This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ritter, G. Articles by Welt, S. Search for Related Content PubMed PubMed Citation Articles by Ritter, G. Articles by Welt, S.

Serological Analysis of Human Anti-Human Antibody Responses in Colon Cancer Patients Treated with Repeated Doses of Humanized Monoclonal Antibody A33

Ludwig Institute for Cancer Research, New York Branch [G. R., L. S. C., C. W., E. C. R., L. J. O., S. W.], and Department of Medicine [S. W.], Memorial Sloan-Kettering Cancer Center, New York, New York 10021

Mouse monoclonal antibody A33 (mAb A33) recognizes a M_r 43,000 cell surface glycoprotein (designated A33) expressed in human colonic epithelium and colon cancer but absent from most other normal tissues. In patients, mAb A33 localizes with high specificity to colon cancer and is retained for up to 6 weeks in the cancer but cleared rapidly from normal colon (5–6 days). As a carrier of ¹²⁵I or ¹³¹I, mAb A33 has shown antitumor activity. Induction of strong human anti-mouse antibody (immunoglobulin; HAMA) responses in patients, however, limits the use of the murine mAb A33 to very few injections. A humanized version of this antibody (huAb A33) has been prepared for Phase I and II clinical studies in patients with colon cancer. In those studies, immunogenicity of huAb A33 has been monitored using a novel, highly sensitive BIACORE method, which allows measurement of human anti-human antibodies (HAHAs) without the use of secondary reagents. We found that 63% (26 of 41) of the patients treated with repeated doses of huAb A33 developed HAHAs against a conformational antigenic determinant located in the V_L and V_H regions of huAb A33. Detailed serological analysis showed two distinct types of HAHAs. HAHA of type I (49% of patients) was characterized by an early onset with peak HAHA levels after 2 weeks of treatment, which declined with ongoing huAb A33 treatment. HAHA of type II (17% of patients) was characterized by a typically later onset of HAHA than in type I and by progressively increasing HAHA levels with each subsequent huAb A33 administration. Colon cancer patients with type I HAHAs did not develop infusion-related adverse events. In contrast, HAHA of type II was indicative of infusion-related adverse events. By using this new method, we were able to distinguish these two types of HAHAs in patients while on antibody treatment, allowing patients to be removed from study prior to the onset of severe infusion-related adverse events.

This article has been cited by other articles:

				E. G. Cafferata, D. R. Maccio, M. V. Lopez, D. L. Viale, C. Carbone, G. Mazzolini, and O. L. Podhajcer A Novel A33 Promoter-Based Conditionally Replicative Adenovirus Suppresses Tumor Growth and Eradicates Hepatic Metastases in Human Colon Cancer Models Clin. Cancer Res., May 1, 2009; 15(9): 3037 - 3049. [Abstract] [Full Text] [PDF]

				U. Petrausch, J. Dernedde, V. Coelho, H. Panjideh, D. Frey, H. Fuchs, E. Thiel, and P. M. Deckert A33scFv Green fluorescent protein, a recombinant single-chain fusion protein for tumor targeting Protein Eng. Des. Sel., December 1, 2007; 20(12): 583 - 590. [Abstract] [Full Text] [PDF]

				A. M. Scott, N. Tebbutt, F.-T. Lee, T. Cavicchiolo, Z. Liu, S. Gill, A. M.T. Poon, W. Hopkins, F. E. Smyth, C. Murone, et al. A Phase I Biodistribution and Pharmacokinetic Trial of Humanized Monoclonal Antibody Hu3s193 in Patients with Advanced Epithelial Cancers that Express the Lewis-Y Antigen Clin. Cancer Res., June 1, 2007; 13(11): 3286 - 3292. [Abstract] [Full Text] [PDF]

				J. L. Klitgaard, V. W. Coljee, P. S. Andersen, L. K. Rasmussen, L. S. Nielsen, J. S. Haurum, and S. Bregenholt Reduced Susceptibility of Recombinant Polyclonal Antibodies to Inhibitory Anti-Variable Domain Antibody Responses J. Immunol., September 15, 2006; 177(6): 3782 - 3790. [Abstract] [Full Text] [PDF]

				A. M. Scott, F.-T. Lee, R. Jones, W. Hopkins, D. MacGregor, J. S. Cebon, A. Hannah, G. Chong, P. U, A. Papenfuss, et al. A Phase I Trial of Humanized Monoclonal Antibody A33 in Patients with Colorectal Carcinoma: Biodistribution, Pharmacokinetics, and Quantitative Tumor Uptake Clin. Cancer Res., July 1, 2005; 11(13): 4810 - 4817. [Abstract] [Full Text] [PDF]

				G. Chong, F. T. Lee, W. Hopkins, N. Tebbutt, J. S. Cebon, A. J. Mountain, B. Chappell, A. Papenfuss, P. Schleyer, P. U, et al. Phase I Trial of 131I-huA33 in Patients with Advanced Colorectal Carcinoma Clin. Cancer Res., July 1, 2005; 11(13): 4818 - 4826. [Abstract] [Full Text] [PDF]

				B. G. Feagan, G. R. Greenberg, G. Wild, R. N. Fedorak, P. Pare, J. W.D. McDonald, R. Dube, A. Cohen, A. H. Steinhart, S. Landau, et al. Treatment of Ulcerative Colitis with a Humanized Antibody to the {alpha}4{beta}7 Integrin N. Engl. J. Med., June 16, 2005; 352(24): 2499 - 2507. [Abstract] [Full Text] [PDF]

				R. Thorpe and S. J Swanson Current Methods for Detecting Antibodies against Erythropoietin and Other Recombinant Proteins Clin. Vaccine Immunol., January 1, 2005; 12(1): 28 - 39. [Full Text] [PDF]

				P. K. E. Borjesson, E. J. Postema, J. C. Roos, D. R. Colnot, H. A. M. Marres, M. H. van Schie, G. Stehle, R. de Bree, G. B. Snow, W. J. G. Oyen, et al. Phase I Therapy Study with 186Re-labeled Humanized Monoclonal Antibody BIWA 4 (Bivatuzumab) in Patients with Head and Neck Squamous Cell Carcinoma Clin. Cancer Res., September 1, 2003; 9(10): 3961S - 3972. [Abstract] [Full Text] [PDF]

				A. M. Scott, G. Wiseman, S. Welt, A. Adjei, F.-T. Lee, W. Hopkins, C. R. Divgi, L. H. Hanson, P. Mitchell, D. N. Gansen, et al. A Phase I Dose-Escalation Study of Sibrotuzumab in Patients with Advanced or Metastatic Fibroblast Activation Protein-positive Cancer Clin. Cancer Res., May 1, 2003; 9(5): 1639 - 1647. [Abstract] [Full Text] [PDF]

				S. Welt, G. Ritter, C. Williams Jr., L. S. Cohen, M. John, A. Jungbluth, E. A. Richards, L. J. Old, and N. E. Kemeny Phase I Study of Anticolon Cancer Humanized Antibody A33 Clin. Cancer Res., April 1, 2003; 9(4): 1338 - 1346. [Abstract] [Full Text] [PDF]

				S. Welt, G. Ritter, C. Williams Jr., L. S. Cohen, A. Jungbluth, E. A. Richards, L. J. Old, and N. E. Kemeny Preliminary Report of a Phase I Study of Combination Chemotherapy and Humanized A33 Antibody Immunotherapy in Patients with Advanced Colorectal Cancer Clin. Cancer Res., April 1, 2003; 9(4): 1347 - 1353. [Abstract] [Full Text] [PDF]

				C. L Smith, N. Dulphy, M. Salio, and V. Cerundolo Immunotherapy of colorectal cancer Br. Med. Bull., December 1, 2002; 64(1): 181 - 200. [Abstract] [Full Text] [PDF]

				P. Tan, D. A. Mitchell, T. N. Buss, M. A. Holmes, C. Anasetti, and J. Foote "Superhumanized" Antibodies: Reduction of Immunogenic Potential by Complementarity-Determining Region Grafting with Human Germline Sequences: Application to an Anti-CD28 J. Immunol., July 15, 2002; 169(2): 1119 - 1125. [Abstract] [Full Text] [PDF]